ORGANIZATION AND BASIS OF PRESENTATION (Tables)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

(a)

As of December 31, 2018, subsidiaries of the Company and its consolidated variable interest entities included the following entities:

Entities	Date of establishment/acquisition	Place of establishment	Percentage of ownership by the Company		Principal activities
Subsidiaries
Ascendium Group Limited (“Ascendium”)	September 10, 2007	British Virgin Islands (“BVI”)	100	%	Investment holding
Concord Medical Investment Management Ltd.	October 28, 2016	BVI	100	%	Investment holding
Our Medical Services Limited (“OMS”)	August 22, 1996	BVI	100	%	Investment holding
Medstar Overseas Ltd. (“Medstar Overseas”)	September 22, 2011	BVI	100	%	Investment holding
Cyber Medical Networks Limited (“Cyber”)	May 26, 2006	Hong Kong	100	%	Investment holding
China Medical Services Holdings Limited (“CMS Holdings”)	July 18, 2008	Hong Kong	100	%	Investment holding
King Cheers Holdings Limited (“King Cheers”)	May 18, 2001	Hong Kong	100	%	Investment holding
Shenzhen Aohua Medical Technology Development Co., Ltd. (“Aohua Technology ”)	February 21, 2008	PRC	60	%	Leasing of medical equipment and provision of management services
Medstar (Shanghai) Leasing Co., Ltd. (“Shanghai Medstar”) **	March 21, 2003	PRC	100	%	Leasing of medical equipment and provision of management services
Beijing MeizhongJiahe Hospital Management Co., Ltd. (“MHM”) *	July 23, 2008	PRC	60	%	Provision of management services
Beijing Yundu Internet Technology Co., Ltd. (“Yundu”)	July 26, 2007	PRC	60	%	Provision of management services
Tianjin Concord Medical Technology Limited (“Tianjin Concord Medical”)	April 22, 2010	PRC	100	%	Leasing of medical equipment and provision of management services
Guangzhou Jinkangshenyou Investment Co., Ltd. (“JKSY”)	August 12, 2010	PRC	100	%	Leasing of medical equipment
Guangzhou Concord Cancer Center (“Guangzhou Concord Cancer Hospital”)	June 29, 2011	PRC	48	%	Group’s medical treatment and service business
CCM (Hong Kong) Medical Investments Limited (“CCM (HK)”)	June 03, 2013	Hong Kong	85.71	%	Investment holding

Entities	Date of establishment/acquisition	Place of establishment	Percentage of ownership by the Company		Principal activities
Shenzhen Concord Medical Investment Limited (“SZ CMS”)	January 10, 2014	PRC	60	%	Investment holding
Shanghai Concord Cancer Center Co., Ltd (“SHC”)	March 17, 2014	PRC	60.26	%	Group’s medical treatment and service business
Global Medical Imaging (HongKong) Ltd. (“GMI”)	May 26, 2014	Hong Kong	100	%	Investment holding
Datong Meizhong Jiahe Cancer Center (“DTMZ”)	October 23, 2014	PRC	60	%	Group’s medical treatment and service business
Wuxi Concord Medical Development Ltd. ("Wuxi Concord”)	December 29, 2015	PRC	100	%	Group’s medical treatment and service business
Concord Hospital Management Group Ltd. (“CHMG”)	July 7, 2015	Hong Kong	100	%	Group’s medical treatment and service business
Beijing Concord Medical Technology Ltd.(“BJCMT”)**	January 4, 2016	PRC	100	%	Provision of management services
Shanghai Taifeng Medical Technology Ltd (“Taifeng”) **	March 30, 2016	PRC	60	%	Group’s medical treatment and service business
Taizhou Concord Leasing Co., Ltd.**	April 20, 2016	PRC	100	%	Group’s medical treatment and service business
Guofu Huimei (Tianjin) Investment Management Partnership Firm (LP) (“Guofu Huimei”) (note 4)	October 8, 2018	PRC	100	%	Investment holding
Beijing Century Friendship Science & Technology Development Co., Ltd (“Beijing Century Friendship”) (note 4)	October 8, 2018	PRC	60	%	Group’s medical treatment and service business
Beijing Proton Medical Center Co., Ltd (“BPMC”) (note 4)	October 8, 2018	PRC	58	%	Group’s medical treatment and service business
Shanghai Meizhong Jiahe Cancer Center Co., Ltd. (“CMCC”) (note 4)	October 8, 2018	PRC	55.42	%	Group’s medical treatment and service business

VIE
ZR ConcordHealthcare Investment Fund SP (“SP”)	November 2016	Cayman Islands	25	%	Investment holding

Subsidiaries of VIE
US Proton Therapy Holdings Limited (“Proton BVI”)	May 16, 2011	BVI	25	%	Investment holding
US Proton Therapy Holdings Limited (“US Proton”)	June 29, 2011	United States of America	25	%	Investment holding
Concord Medical Services (International) Pte. Ltd. (“China Medstar”) (formerly known as China Medstar Pte. Limited)	August 8, 2003	Singapore	25	%	Investment holding
Concord Healthcare Singapore Pte. Ltd. (“CHS”)	April 1, 2015	Singapore	25	%	Group’s medical treatment and service business

* On August 27, 2015, the Group changed the name of CMS Hospital Management Co., Ltd. (“CHM”) to Beijing MeizhongJiahe Hospital Management Co., Ltd. (“MHM”), providing management service to the Group’s existing network.

Schedule of financial information

The following tables represent the financial information of the VIE and its subsidiaries as of December 31, 2017 and 2018 and for the years ended December 31, 2017 and 2018 before eliminating the intercompany balances and transactions between the VIE and its subsidiaries and other entities within the Group:

	As at December 31,		As at December 31,
	2017		2018		2018
	RMB		RMB		US$
ASSETS
Current assets:
Cash		13,161		15,935		2,318
Restricted cash, current portion		42		-		-
Accounts receivable (net of allowance of RMB 73 (US$ 11 ) as of December 31, 2018)		3,985		4,494		654
Inventories		1,399		1,946		283
Prepayments and other current assets		1,988		1,986		289
Amount due from inter-companies*		-		80,523		11,711

Total current assets	20,575	104,884	15,255

Non-current assets:
Property, plant and equipment, net	279,240	281,395	40,927
Intangible assets, net	202	100	15
Deposits for non-current assets	172	-	-
Long-term investments	195,040	31,496	4,581
Other non-current assets	481	464	67
Total non-current assets	475,135	313,455	45,590

Total assets	495,710	418,339	60,845

	As at December 31,		As at December 31,
	2017		2018		2018
	RMB		RMB		US$
Current liabilities:
Accounts payable		1,978		462		67
Accrued expenses and other liabilities		21,321		42,681		6,208
Income tax payable		-		2,870		417
Amount due to inter-companies*		54,563		-		-
Total current liabilities		77,862		46,013		6,692

Non-current liabilities:
Deferred tax liabilities		8,316		-		-
Accrued unrecognized tax benefits & surcharge, non current portion		-		20,208		2,939
Mandatorily redeemable noncontrolling interests		396,281		434,216		63,154
Total non-current liabilities		404,597		454,424		66,093

Total liabilities		482,459		500,437		72,785

* Amount due from/to inter-companies represented receivable/payable balances of VIE and its subsidiaries due from/to other subsidiaries within the Group.

	As at December 31,			As at December 31,
	2017			2018			2018
	RMB			RMB			US$
Net revenues		28,673			41,350			6,014
Net loss		(141,188	)		(95,788	)		(13,931	)

	As at December 31,			As at December 31,
	2017			2018			2018
	RMB			RMB			US$
Net cash used in operating activities		(54,113	)		(260,884	)		(37,944	)
Net cash (used in) generated from investing activities		(5,582	)		221,130			32,162
Net cash generated from financing activities		56,787			41,886			6,092
Exchange rate effect on cash, net		748			600			87
(Decrease) increase in cash and cash equivalents		(2,160	)		2,732			397

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details